Melanocortin Receptor Agonist
PT-141 (Bremelanotide) is a synthetic peptide analogue of alpha-melanocyte-stimulating hormone (α-MSH). Unlike traditional treatments for sexual dysfunction that act peripherally on the vascular system, PT-141 acts centrally by stimulating melanocortin receptors in the central nervous system. This direct neurological mechanism makes it a unique subject for research into the treatment of Hypoactive Sexual Desire Disorder (HSDD) and the broader study of melanocortin pathways in behavioral responses.
Absorption and penetration into the central nervous system. Subjects may experience mild flushing or transient nausea as melanocortin receptors begin activation.
| Compound | Primary Mechanism | Key Benefit | Admin. |
|---|---|---|---|
| PT-141 | Melanocortin Agonist (CNS) | Direct neurological libido enhancement | SubQ |
| Melanotan II | Melanocortin Agonist | Melanogenesis & libido enhancement | SubQ |
| Sildenafil | PDE5 Inhibitor | Peripheral vasodilation (blood flow) | Oral |
| Oxytocin | Neuropeptide | Social bonding & behavioral responses | Nasal/SubQ |
PT-141 directly targets the central nervous system, bypassing the vascular pathways typically utilized by traditional treatments for sexual dysfunction.
Following systemic absorption, the peptide crosses the blood-brain barrier to access central neural pathways.
Binds non-selectively to melanocortin receptors, primarily MC3R and MC4R, which are heavily involved in behavioral and sexual responses.
Stimulates neural pathways that increase sexual desire and arousal directly from the brain, independently of local blood flow mechanics.
Approximately 2.7 hours, though neurological effects can persist for 12-24 hours.
High via subcutaneous injection. Not suitable for oral administration due to rapid peptide degradation.
Metabolized via proteolytic degradation and cleared through renal and hepatic pathways.
Melanocortin receptors (MC3R and MC4R) in the central nervous system.
PT-141 has been extensively studied for its efficacy in treating Hypoactive Sexual Desire Disorder (HSDD) and its unique central mechanism.
Explores how central melanocortin receptor activation influences behavioral and sexual responses.
BEHAVIORAL RESEARCHA review of clinical data supporting the efficacy of PT-141 in treating Hypoactive Sexual Desire Disorder.
PHARMACOLOGYComparative analysis of PT-141 and traditional PDE5 inhibitors in research models.
Explore research-use products associated with this compound profile, including available formats, related blends, and supporting lab documentation where available.
Deeper research-focused questions about PT-141, Bremelanotide, melanocortin receptor agonist research, alpha-MSH analogue biology, MC3R and MC4R signaling models, storage, and batch documentation.
PT-141, also known as Bremelanotide, is a synthetic melanocortin receptor agonist research compound commonly discussed in relation to alpha-MSH analogue biology, MC3R and MC4R pathway models, central melanocortin signaling, neuroendocrine research, and melanocortin receptor pharmacology. On this site, PT-141 is positioned strictly as a laboratory research reference compound.
PT-141 is the investigational research code commonly associated with Bremelanotide. In scientific and regulatory literature, Bremelanotide is the more formal compound name, while PT-141 is still widely used in research catalogs and search behavior. For SEO clarity, the page should include both PT-141 and Bremelanotide because visitors may search either term.
Yes. PT-141 / Bremelanotide is commonly described as a synthetic cyclic heptapeptide, meaning it is a peptide-based compound with a seven-residue cyclic structure. It is different from small-molecule research compounds such as Bromantane or 5-Amino-1MQ, and different from coenzyme compounds such as NAD+. For site structure, PT-141 belongs in the melanocortin peptide research category.
PT-141 is commonly discussed within the alpha-melanocyte-stimulating hormone, or alpha-MSH, analogue research family. Alpha-MSH is an endogenous melanocortin peptide that interacts with melanocortin receptor pathways. PT-141 is studied as a synthetic melanocortin receptor agonist, with research emphasis often placed on MC3R and MC4R signaling models rather than MC1R-focused pigmentation pathway research.
Melanocortin receptors are G protein-coupled receptor systems involved in several research areas, including pigmentation biology, energy-balance models, neuroendocrine signaling, inflammatory pathway research, and central nervous system signaling. PT-141 is most commonly discussed in relation to melanocortin receptor agonist research, especially MC3R and MC4R pathway models.
PT-141 is most often discussed around MC3R and MC4R pathway research, with broader melanocortin receptor agonist activity also relevant in scientific literature. MC3R and MC4R are commonly associated with central melanocortin signaling, neuroendocrine models, appetite and energy-balance research, and behavioral pathway studies. A research-use page should frame these as receptor and pathway models rather than clinical, consumer, or self-use claims.
MC4R is frequently discussed in PT-141 research because it is a central melanocortin receptor pathway connected to neuroendocrine signaling, energy-balance models, and behavioral pathway research. Including MC4R terminology gives a PT-141 page stronger scientific depth than simply describing the compound as a generic melanocortin peptide. However, MC4R discussion should remain limited to laboratory and receptor-pathway research.
PT-141 and Melanotan II are related within the melanocortin analogue research category, but they should not be treated as interchangeable. Melanotan II is more commonly discussed across broader melanocortin receptor activity, including pigmentation-pathway research through MC1R. PT-141 is more commonly positioned around Bremelanotide, MC3R and MC4R signaling models, and central melanocortin receptor research. Separate pages are useful because the search intent and mechanism emphasis are different.
PT-141 and Melanotan I both connect to the broader alpha-MSH and melanocortin research family, but they are used to discuss different pathway categories. Melanotan I is generally associated with MC1R, pigmentation biology, and photoprotection-related models. PT-141 is more closely associated with Bremelanotide terminology, melanocortin receptor agonist research, and MC3R/MC4R central signaling models.
No. PT-141 is not the same type of research compound as Kisspeptin, GnRH, or HCG. PT-141 belongs in the melanocortin receptor agonist research category. Kisspeptin and GnRH are more commonly discussed in reproductive neuroendocrine signaling, while HCG is a glycoprotein hormone associated with LH/CG receptor signaling and gonadotropin pathway research. These compounds may all touch neuroendocrine research themes, but the receptor systems are different.
PT-141 is commonly associated with research areas involving melanocortin receptor pharmacology, alpha-MSH analogue biology, MC3R signaling, MC4R signaling, central melanocortin pathways, neuroendocrine signaling, behavioral pathway models, receptor selectivity studies, cyclic peptide structure, and comparative research against Melanotan I or Melanotan II. It is best positioned as a melanocortin receptor agonist research peptide rather than a growth hormone secretagogue, repair peptide, metabolic receptor agonist, or mitochondrial peptide.
PT-141 research discussions may involve endpoints related to melanocortin receptor binding, MC3R activity, MC4R activity, cAMP-linked signaling, central melanocortin pathway markers, receptor selectivity, neuroendocrine signaling models, behavioral pathway assays, and comparative analysis against other alpha-MSH analogues. The exact endpoints depend on the study model, receptor focus, analytical methods, and whether the research is focused on melanocortin pharmacology, receptor selectivity, or central pathway signaling.
PT-141 is the research code associated with Bremelanotide, while Vyleesi is a regulated prescription product containing Bremelanotide injection. A research-use PT-141 product should not be confused with Vyleesi, any approved medication, any prescription product, any pharmacy product, or any clinical protocol. This page uses PT-141 and Bremelanotide terminology for scientific reference and laboratory research positioning only.
PT-141 should not be presented on this page as a dietary supplement, wellness product, sexual function product, prescription alternative, compounded pharmacy product, or self-administered compound. Although Bremelanotide has a regulated prescription-drug context, research-use PT-141 material sold by Symbiotic Pharmaceuticals should not be confused with any approved medication, branded drug product, clinical protocol, or consumer health product. This page is written only for educational reference and laboratory research positioning.
Storage requirements can vary by product format, batch, and label instructions. For research handling, follow the product label and applicable laboratory storage standards. In general, research peptides should be protected from unnecessary heat, light, moisture, contamination, oxidation, and repeated temperature changes because these conditions may affect long-term stability and handling quality.
Available certificates of analysis and batch documentation can be reviewed through the Lab Results / COA page. Documentation availability may vary by product and inventory lot. Where available, batch documentation may include product identification, purity-focused testing references, assay references where applicable, and supporting analytical documentation.
Yes. PT-141 products listed on Symbiotic Pharmaceuticals are intended for laboratory research and analytical reference use only. They are not intended for human consumption, animal consumption, diagnostic use, therapeutic use, sexual function use, wellness use, prescription use, compounded pharmacy use, injection use, or self-administration. Any discussion on this page is provided for educational and research-reference purposes only.
The information provided in this resource hub is for educational and informational purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease.
